Pembrolizumab vs Tofacitinib
Pembrolizumab vs Tofacitinib: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Tofacitinib.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.
Pharmacokinetics
Half-life: Pembrolizumab β 26 days; Tofacitinib β 3.2 hours.
Chemical Properties
Molecular Formula: Tofacitinib β C16H20N6O.
Molecular Weight: Tofacitinib β 312.3700 g/mol.
Type: Pembrolizumab β Antibody; Tofacitinib β Small molecule.